Neurogene (NGNE) Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.

Which has higher earnings & valuation, ARQT or NGNE?

Neurogene has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$59.61M	24.11	-$262.14M	-$1.79	-6.86
Neurogene	N/A	N/A	-$36.32M	N/A	N/A

Which has more risk & volatility, ARQT or NGNE?

Arcutis Biotherapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Does the MarketBeat Community prefer ARQT or NGNE?

Arcutis Biotherapeutics received 33 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 64.13% of users gave Arcutis Biotherapeutics an outperform vote.

Company	Underperform	Outperform
Arcutis Biotherapeutics	Outperform Votes 59 64.13%	Underperform Votes 33 35.87%
Neurogene	Outperform Votes 26 100.00%	Underperform Votes No Votes

Do institutionals & insiders have more ownership in ARQT or NGNE?

52.4% of Neurogene shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 9.9% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts rate ARQT or NGNE?

Arcutis Biotherapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 26.22%. Neurogene has a consensus price target of $60.83, suggesting a potential upside of 168.70%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Neurogene	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

Does the media prefer ARQT or NGNE?

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 7 mentions for Neurogene. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Neurogene's score of 0.46 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ARQT or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Neurogene's return on equity of -32.81% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-140.97%	-119.11%	-45.95%
Neurogene	N/A	-32.81%	-27.96%

Summary

Neurogene beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks.